Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
298 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Glaucoma - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Glaucoma - Pipeline Review, H2 2016', provides an overview of the Glaucoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects - The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Glaucoma Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Glaucoma - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 6 Glaucoma Overview 7 Therapeutics Development 8 Glaucoma - Therapeutics under Development by Companies 10 Glaucoma - Therapeutics under Investigation by Universities/Institutes 16 Glaucoma - Pipeline Products Glance 17 Glaucoma - Products under Development by Companies 21 Glaucoma - Products under Investigation by Universities/Institutes 27 Glaucoma - Companies Involved in Therapeutics Development 28 Glaucoma - Therapeutics Assessment 87 Drug Profiles 103 Glaucoma - Dormant Projects 263 Glaucoma - Discontinued Products 271 Glaucoma - Product Development Milestones 273 Appendix 284
List of Tables
Number of Products under Development for Glaucoma, H2 2016 21 Number of Products under Development for Glaucoma - Comparative Analysis, H2 2016 22 Number of Products under Development by Companies, H2 2016 24 Number of Products under Development by Companies, H2 2016 (Contd..1) 25 Number of Products under Development by Companies, H2 2016 (Contd..2) 26 Number of Products under Development by Companies, H2 2016 (Contd..3) 27 Number of Products under Development by Companies, H2 2016 (Contd..4) 28 Number of Products under Investigation by Universities/Institutes, H2 2016 29 Comparative Analysis by Late Stage Development, H2 2016 30 Comparative Analysis by Clinical Stage Development, H2 2016 31 Comparative Analysis by Early Stage Development, H2 2016 32 Comparative Analysis by Unknown Stage Development, H2 2016 33 Products under Development by Companies, H2 2016 34 Products under Development by Companies, H2 2016 (Contd..1) 35 Products under Development by Companies, H2 2016 (Contd..2) 36 Products under Development by Companies, H2 2016 (Contd..3) 37 Products under Development by Companies, H2 2016 (Contd..4) 38 Products under Development by Companies, H2 2016 (Contd..5) 39 Products under Investigation by Universities/Institutes, H2 2016 40 Glaucoma - Pipeline by AC Immune SA, H2 2016 41 Glaucoma - Pipeline by Acadia Pharmaceuticals Inc., H2 2016 42 Glaucoma - Pipeline by Advanced Refractive Technologies, Inc., H2 2016 43 Glaucoma - Pipeline by Aerie Pharmaceuticals, Inc., H2 2016 44 Glaucoma - Pipeline by Allergan Plc, H2 2016 45 Glaucoma - Pipeline by Altacor Limited, H2 2016 46 Glaucoma - Pipeline by Amakem NV, H2 2016 47 Glaucoma - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2016 48 Glaucoma - Pipeline by Amgen Inc., H2 2016 49 Glaucoma - Pipeline by Astellas Pharma Inc., H2 2016 50 Glaucoma - Pipeline by Bausch & Lomb Incorporated, H2 2016 51 Glaucoma - Pipeline by BioAxone BioSciences, Inc., H2 2016 52 Glaucoma - Pipeline by Bionure Farma, S.L., H2 2016 53 Glaucoma - Pipeline by Coronis Partners Ltd., H2 2016 54 Glaucoma - Pipeline by D. Western Therapeutics Institute, Inc., H2 2016 55 Glaucoma - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56 Glaucoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 57 Glaucoma - Pipeline by Gilead Sciences, Inc., H2 2016 58 Glaucoma - Pipeline by Glaukos Corporation, H2 2016 59 Glaucoma - Pipeline by Graybug Vision Inc, H2 2016 60 Glaucoma - Pipeline by Handok Inc., H2 2016 61 Glaucoma - Pipeline by HitGen LTD, H2 2016 62 Glaucoma - Pipeline by Icon Bioscience, Inc., H2 2016 63 Glaucoma - Pipeline by ID Pharma Co., Ltd., H2 2016 64 Glaucoma - Pipeline by InMed Pharmaceuticals Inc., H2 2016 65 Glaucoma - Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 66 Glaucoma - Pipeline by InSite Vision Incorporated, H2 2016 67 Glaucoma - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 68 Glaucoma - Pipeline by Isarna Therapeutics GmbH, H2 2016 69 Glaucoma - Pipeline by Kala Pharmaceuticals, Inc., H2 2016 70 Glaucoma - Pipeline by Kowa Company, Ltd., H2 2016 71 Glaucoma - Pipeline by Kukje Pharmaceutical Industry Co., Ltd., H2 2016 72 Glaucoma - Pipeline by Laboratoires Thea S.A., H2 2016 73 Glaucoma - Pipeline by Laboratorios Sophia S.A. de C.V., H2 2016 74 Glaucoma - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2016 75 Glaucoma - Pipeline by Lexicon Pharmaceuticals, Inc., H2 2016 76 Glaucoma - Pipeline by Merck & Co., Inc., H2 2016 77 Glaucoma - Pipeline by Nemus Bioscience, Inc., H2 2016 78 Glaucoma - Pipeline by NicOx S.A., H2 2016 79 Glaucoma - Pipeline by NoNO, Inc., H2 2016 80 Glaucoma - Pipeline by Novaliq GmbH, H2 2016 81 Glaucoma - Pipeline by Ocular Therapeutix, Inc., H2 2016 82 Glaucoma - Pipeline by Oculis ehf, H2 2016 83 Glaucoma - Pipeline by Ohr Pharmaceutical Inc., H2 2016 84 Glaucoma - Pipeline by Otsuka Holdings Co., Ltd., H2 2016 85 Glaucoma - Pipeline by Oxford BioMedica Plc, H2 2016 86 Glaucoma - Pipeline by Profarma, H2 2016 87 Glaucoma - Pipeline by pSivida Corp., H2 2016 88 Glaucoma - Pipeline by Quark Pharmaceuticals, Inc., H2 2016 89 Glaucoma - Pipeline by Quethera Limited, H2 2016 90 Glaucoma - Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 91 Glaucoma - Pipeline by Sanofi, H2 2016 92 Glaucoma - Pipeline by Santen Pharmaceutical Co., Ltd., H2 2016 93 Glaucoma - Pipeline by Senju Pharmaceutical Co., Ltd., H2 2016 94 Glaucoma - Pipeline by Shire Plc, H2 2016 95 Glaucoma - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 96 Glaucoma - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 97 Glaucoma - Pipeline by Sylentis S.A.U., H2 2016 98 Glaucoma - Pipeline by ViSci Ltd., H2 2016 99 Assessment by Monotherapy Products, H2 2016 100 Assessment by Combination Products, H2 2016 101 Number of Products by Stage and Target, H2 2016 103 Number of Products by Stage and Mechanism of Action, H2 2016 108 Number of Products by Stage and Route of Administration, H2 2016 113 Number of Products by Stage and Molecule Type, H2 2016 115 Glaucoma - Dormant Projects, H2 2016 276 Glaucoma - Dormant Projects (Contd..1), H2 2016 277 Glaucoma - Dormant Projects (Contd..2), H2 2016 278 Glaucoma - Dormant Projects (Contd..3), H2 2016 279 Glaucoma - Dormant Projects (Contd..4), H2 2016 280 Glaucoma - Dormant Projects (Contd..5), H2 2016 281 Glaucoma - Dormant Projects (Contd..6), H2 2016 282 Glaucoma - Dormant Projects (Contd..7), H2 2016 283 Glaucoma - Discontinued Products, H2 2016 284 Glaucoma - Discontinued Products (Contd..1), H2 2016 285
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
